NasdaqCM:NKTRPharmaceuticals
Assessing Nektar Therapeutics (NKTR) Valuation After A Sharp Multi‑Month Share Price Run
Company overview and recent stock performance
Nektar Therapeutics (NKTR) has drawn fresh attention after an extended run in its share price, with the stock showing strong returns over the past 3 months and the past year.
For context, Nektar is a US based biopharmaceutical company focused on immunotherapy, with a pipeline that includes rezpegaldesleukin in Phase 2b for autoimmune and inflammatory diseases, plus several earlier stage candidates targeting autoimmune and fibrotic conditions, as...